PMID- 35413499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220506
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 20
DP  - 2022 Jun
TI  - Novel IL-15 dendritic cells have a potent immunomodulatory effect in 
      immunotherapy of multiple myeloma.
PG  - 101413
LID - S1936-5233(22)00075-4 [pii]
LID - 10.1016/j.tranon.2022.101413 [doi]
LID - 101413
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells, and have thus 
      been used in clinical cancer vaccines. However, the effects of DC vaccines are 
      still limited, leading researchers to explore novel ways to make them effective. 
      In this study, we investigated whether human monocyte-derived DCs generated via 
      the addition of interleukin 15 (IL-15) had a higher capacity to induce 
      antigen-specific T cells compared to conventional DCs. We isolated CD14(+) 
      monocytes from peripheral blood from multiple myeloma (MM) patients, and induced 
      immature DCs with granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
      IL-4 in the presence or absence of IL-15 for 4-6 days. Then we generated mature 
      DCs (mDCs) with lipopolysaccharide for another 2 days [IL-15 mDCs (6 days), IL-15 
      mDCs (8 days), and conventional mDCs (8 days)]. IL-15 mDCs (6 days) showed higher 
      expression of MHC I and II, CD40, CD86, and CCR7, and the secretion of IFN-gamma was 
      significantly higher compared to conventional mDCs. IL-15 mDCs (6 days) showed 
      superior polarization of naive T cells toward Th1 cells and a higher proportion 
      of activated T cells, cytokine-induced killer (CIK) cells, and natural killer 
      (NK) cells for inducing strong cytotoxicity against myeloma cells, and lower 
      proportion of regulatory T cells compared to conventional mDCs. These data imply 
      that novel multipotent mDCs generated by the addition of IL-15, which can be 
      cultivated in 6 days, resulted in outstanding activation of T cells, CIK cells 
      and NK cells, and may facilitate cellular immunotherapy for cancer patients.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Chu, Tan-Huy
AU  - Chu TH
AD  - BioMedical Sciences Graduate Program, Chonnam National University, South Korea; 
      Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Vo, Manh-Cuong
AU  - Vo MC
AD  - Institute of Research and Development, Duy Tan University, Danang, Vietnam; 
      Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Lakshmi, Thangaraj Jaya
AU  - Lakshmi TJ
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Ahn, Seo-Yeon
AU  - Ahn SY
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Kim, Mihee
AU  - Kim M
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Song, Ga-Young
AU  - Song GY
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Yang, Deok-Hwan
AU  - Yang DH
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Ahn, Jae-Sook
AU  - Ahn JS
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Kim, Hyeoung-Joon
AU  - Kim HJ
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea.
FAU - Jung, Sung-Hoon
AU  - Jung SH
AD  - Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea. Electronic address: 
      shglory@hanmail.net.
FAU - Lee, Je-Jung
AU  - Lee JJ
AD  - BioMedical Sciences Graduate Program, Chonnam National University, South Korea; 
      Department of Hematology-Oncology, Chonnam National University Hwasun Hospital 
      and Chonnam National University Medical School, South Korea. Electronic address: 
      drjejung@chonnam.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20220409
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC9006865
OTO - NOTNLM
OT  - Immunology
OT  - T cells
OT  - cytokine induced killer cells
OT  - multiple myeloma
OT  - natural killer cells
COIS- The authors declare no conflicts of interest.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/13 06:01
PMCR- 2022/04/09
CRDT- 2022/04/12 20:11
PHST- 2022/02/07 00:00 [received]
PHST- 2022/03/25 00:00 [revised]
PHST- 2022/03/28 00:00 [accepted]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/13 06:01 [medline]
PHST- 2022/04/12 20:11 [entrez]
PHST- 2022/04/09 00:00 [pmc-release]
AID - S1936-5233(22)00075-4 [pii]
AID - 101413 [pii]
AID - 10.1016/j.tranon.2022.101413 [doi]
PST - ppublish
SO  - Transl Oncol. 2022 Jun;20:101413. doi: 10.1016/j.tranon.2022.101413. Epub 2022 
      Apr 9.